Phase II Study of Tumor Cell-derived Microparticles Used as Vectors of Chemotherapeutic Drugs to Treat Malignant Ascites and Pleural Effusion
Ascites or pleural effusion were first removed from patients. The patients were then locally
injected with microparticles packaging chemotherapeutic drugs 4 times a week. The
therapeutic effects and side effects were recorded.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Volume of Ascites or Pleural Effusion
10 months
Yes
Bo Huang, Ph.D
Principal Investigator
Huazhong University of Science and Technology
United States: Food and Drug Administration
Soundny Biotech
NCT01854866
March 2013
March 2014
Name | Location |
---|